SHERIDAN, WYOMING – November 09, 2024 – Novartis, a global healthcare company, recently released promising data on its Kesimpta® (ofatumumab) treatment for relapsing multiple sclerosis (RMS). The findings, presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 Annual Meeting, highlight the long-term benefits of Kesimpta for both first-line and switch patients. Relapsing multiple sclerosis is a chronic disease that affects the central nervous system, disrupting the flow of information within the brain, and between the brain and body. It is characterized by periods of relapse (disease activity) and remission (recovery). Kesimpta is a targeted B-cell therapy that works by reducing the number of B-cells, a type of immune cell thought to play a key role in MS attacks.

Novartis' Iptacopan Shows Promising Results in Phase III Trial for IgA Nephropathy SHERIDAN, WYOMING – November 09, 2024 – Novartis, a global healthcare leader, has announced exciting news from its Phase III APPLAUSE-IgAN study. Iptacopan, an investigational oral medication, has demonstrated significant potential in treating IgA nephropathy (IgAN), a rare and progressive kidney disease. This breakthrough offers renewed hope for young adults living with this challenging condition. Understanding IgA Nephropathy IgAN, often diagnosed in young adults, is a complex autoimmune disease where the body's immune system mistakenly attacks the kidneys. This leads to inflammation and damage, potentially resulting in kidney failure. Current treatments have limitations in addressing the root cause of the disease, highlighting the urgent need for more effective therapies.

SHERIDAN, WYOMING – November 09, 2024 – In a significant advancement for healthcare diagnostics, bioMérieux, a world leader in in vitro diagnostics, announces the launch of VIDAS® VITAMIN B12 TOTAL, a groundbreaking automated test designed to revolutionize the detection and management of vitamin B12 deficiency. This innovative test, which received CE marking, offers a rapid and efficient method for measuring vitamin B12 concentration in human serum or plasma, providing healthcare professionals with a critical tool for accurate diagnosis and timely treatment.

SHERIDAN, WYOMING – November 08, 2024 – Sanofi, a leading global biopharmaceutical company, has announced outstanding results for the third quarter of 2024, showcasing robust financial performance and significant progress in its innovative product pipeline. The company's dedication to providing healthcare solutions for patients worldwide is reflected in its impressive double-digit sales growth and groundbreaking achievements in research and development. Sanofi's Q3 2024 sales surged by 15.7% at constant exchange rates (CER), reaching €13,438 million. Business earnings per share (EPS) also saw a significant increase, rising by 12.2% on a reported basis and 17.6% at CER to reach €2.86. This strong performance was fueled by better-than-expected vaccine sales, particularly for influenza and Beyfortus (RSV), and the continued strong growth of Dupixent, the company's leading immunology drug.

SHERIDAN, WYOMING – November 8, 2024 – Sanofi, a global biopharmaceutical company, is taking a bold stance in the fight against cancer by launching a comprehensive program designed to support employees impacted by the disease. Recognizing the profound impact cancer can have on individuals and their families, Sanofi's "Cancer & Work: Acting Together" initiative provides a 360° approach to addressing the financial, emotional, social, and professional needs of its colleagues. "We're creating an environment where everyone is supported to bring their best self to work," says a Sanofi spokesperson. This commitment is evidenced by Sanofi's participation in Publicis' #WorkingWithCancer global pledge, a public declaration to combat cancer and its associated stigmas in the workplace.

SHERIDAN, WYOMING – November 07, 2024 – Abbott, a global healthcare leader, is proud to announce the formation of Team Abbott, a worldwide community of runners united by their passion for health and fitness. This initiative underscores Abbott's commitment to helping people live their best lives through the power of good health. The inspiration behind Team Abbott stems from the recognition that marathons, while individual races, are ultimately a team sport. "Ask anyone who has run one and they’ll tell you: Marathons are a team sport," says an Abbott spokesperson. "Literally speaking, no, marathons can’t be relayed by a team of athletes, nor are they won by team organizations. But the process of training to run 26.2 miles, and attaining the health needed to do so, is a team effort."

SHERIDAN, WYOMING – November 7, 2024 – In an era marked by growing health concerns and disparities, Tanzania is taking proactive strides to bolster its healthcare system. Through strategic investment in medical education and capacity building, the nation is fostering a skilled healthcare workforce to address its unique challenges and improve the well-being of its citizens. A collaborative endeavor between the Tanzanian Ministry of Health, Siemens Healthineers, and Muhimbili National Hospital (MNH) has yielded a specialized training program for medical engineers and radiographers. Over the past two years, this initiative has empowered more than 100 healthcare professionals with advanced skills in operating state-of-the-art imaging equipment.

SHERIDAN, WYOMING – November 07, 2024 – In an effort to combat the largest blood shortage in a generation, Abbott and the Big Ten Conference have joined forces to launch "The We Give Blood Drive," a conference-wide competition aimed at increasing blood donations. This initiative taps into the competitive spirit of Big Ten universities and their fans, encouraging them to give back to their communities while vying for a $1 million prize and a trip to the 2024 Discover Big Ten Football Championship Game. The competition, which kicked off on September 26th, has already seen tremendous support, with over 8,000 Big Ten fans, students, and alumni donating blood.